Acquired by Novartis
Industries BiotechnologyHealth CarePharmaceuticalHeadquarters Regions Great Lakes, Midwestern US Closed Date Oct 18, 2018 Founded Date 1996 Founders Philip Low, Ron Ellis Operating Status Closed Last Funding Type Debt Financing Legal Name Endocyte, Inc.
Stock Symbol NASDAQ:ECYT Company Type For Profit
Contact Email info@endocyte.com Phone Number (765) 463-7175
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers
of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
Transaction Name Endocyte acquired by NovartisAcquired by NovartisAnnounced Date Oct 18, 2018